UnknownNCT06160232
Psilocybin-Assisted Therapy for Severe Addiction
Medication studyAges 21–64Belgium
Understand this study
Who could participate?
Listed age limits: 21 years to 64 years.
- Listed locations
- BrusselsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 15, 2024
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 62
- Sponsor
- Brugmann University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium
- Age range
- From 21 Years to 64 Years
- Official registry ID
- NCT06160232
- Official title
Show the full official title
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Brussels
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Brugmann University Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin (high dose) and Active placebo (low dose of psilocybin).
Who can participate?
Listed age limits: 21 years to 64 years.
